Optimer Seeks EU Approval

7/29/10

San Diego-based Optimer Pharmaceuticals (NASDAQ: OPTR) said today it has filed an application for approval in the European Union to start marketing fidaxomicin to treat C.difficile bacterial infections. The drug has passed a pair of pivotal clinical trials, showing that it was roughly equal to standard vancomycin therapy at curing patients initially, but the new treatment was better at preventing recurrences, which can be life-threatening. Optimer plans to seek FDA approval later in 2010.

By posting a comment, you agree to our terms and conditions.